Arrowhead Prescription drugs is ditching a pulmonary drug after it did not hit the mark in a section 1/2 trial final yr. However the biotech is filling up its quiver with at the very least two extra prospects in this system as a replacemen
Executives reported the pipeline modifications within the firm’s fourth-quarter earnings (PDF) Wednesday afternoon. President and CEO Chris Anzalone, Ph.D, stated Arrowhead is making progress on the ENaC goal, or epithelial sodium channels, which is a possible pathway in cystic fibrosis to rehydrate airway surfaces and enhance the work of mucus within the physique.
However that progress has not been seen with ARO-ENaC. The corporate paused a section 1/2 cystic fibrosis research final yr after rats in a preclinical research confirmed sudden lung irritation. Anzalone stated Arrowhead “will doubtless not proceed” with the candidate.
As a substitute, Arrowhead has two or three next-gen compounds within the works to fill the hole. These candidates “seem to have favorable pharmacologic properties in comparison with ARO-ENaC,” in keeping with the CEO.
RELATED: Arrowhead slams brakes on early-stage cystic fibrosis research after rat research triggers lung irritation considerations
“So, we’re doubtless altering horses within the ENaC program, however we now have not but settled on which new horse,” Anzalone stated.
The choice to desert ARO-ENaC was not a shock to RBC Capital Markets analysts, who identified the discontinuation in a observe to purchasers.
Arrowhead’s James Hamilton, M.D., senior VP, discovery and translational medication, stated the preclinical irritation seen in rats has since been confirmed in nonhuman primates as nicely.
Hamilton stated the issues may have stemmed from an overdose within the preclinical animal research, which may have been tweaked to discover a cleaner toxicity profile for future trials.
“That might present a quicker path again to the clinic, however we determined that the higher long-term path is to give attention to next-generation ENaC candidates,” he stated.
RELATED: Arrowhead can see the Horizon with $700M biobucks pact for an early RNA gout med
Arrowhead plans to file two new scientific trial functions with the FDA for ARO-RAGE and ARO-MUC5AC in numerous muco-obstructive and inflammatory pulmonary circumstances over the following quarter, in keeping with the CEO. Preclinical information is anticipated on the American Thoracic Society assembly in Might.
Hamilton stated that these medicine have been examined at a decrease publicity degree than the first-generation ENaC program and seem like stronger. The expectation is that much less of the drug can be utilized with much less frequent dosing.
A 3rd software can be anticipated by the top of the yr in an unnamed goal and illness space.